152 related articles for article (PubMed ID: 26038231)
1. Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.
Tveita AA; Schjesvold F; Haabeth OA; Fauskanger M; Bogen B
Cancer Res; 2015 Aug; 75(16):3268-78. PubMed ID: 26038231
[TBL] [Abstract][Full Text] [Related]
2. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.
Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B
Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679
[TBL] [Abstract][Full Text] [Related]
3. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma.
Bogen B
Eur J Immunol; 1996 Nov; 26(11):2671-9. PubMed ID: 8921954
[TBL] [Abstract][Full Text] [Related]
4. CD4
Bogen B; Fauskanger M; Haabeth OA; Tveita A
Cancer Immunol Immunother; 2019 Nov; 68(11):1865-1873. PubMed ID: 31448380
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display.
Tveita A; Fauskanger M; Bogen B; Haabeth OA
Oncotarget; 2016 Oct; 7(41):67175-67182. PubMed ID: 27626487
[TBL] [Abstract][Full Text] [Related]
6. Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells.
Tveita AA; Schjesvold FH; Sundnes O; Haabeth OA; Haraldsen G; Bogen B
Eur J Immunol; 2014 Sep; 44(9):2625-37. PubMed ID: 24846412
[TBL] [Abstract][Full Text] [Related]
7. Primary antitumor immune response mediated by CD4+ T cells.
Corthay A; Skovseth DK; Lundin KU; Røsjø E; Omholt H; Hofgaard PO; Haraldsen G; Bogen B
Immunity; 2005 Mar; 22(3):371-83. PubMed ID: 15780993
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
Dembic Z; Schenck K; Bogen B
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
[TBL] [Abstract][Full Text] [Related]
9. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
[TBL] [Abstract][Full Text] [Related]
10. Clonal deletion of thymocytes as a tumor escape mechanism.
Lauritzsen GF; Hofgaard PO; Schenck K; Bogen B
Int J Cancer; 1998 Oct; 78(2):216-22. PubMed ID: 9754655
[TBL] [Abstract][Full Text] [Related]
11. CD4
Haabeth OAW; Fauskanger M; Manzke M; Lundin KU; Corthay A; Bogen B; Tveita AA
Cancer Res; 2018 Aug; 78(16):4573-4585. PubMed ID: 29752262
[TBL] [Abstract][Full Text] [Related]
12. A mouse model for immunotherapy of myeloma.
Bogen B
Hematol J; 2002; 3(5):224-9. PubMed ID: 12391539
[TBL] [Abstract][Full Text] [Related]
13. Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.
Corthay A; Lorvik KB; Bogen B
Scand J Immunol; 2011 Jun; 73(6):527-30. PubMed ID: 21388431
[TBL] [Abstract][Full Text] [Related]
14. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
15. Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.
Arina A; Karrison T; Galka E; Schreiber K; Weichselbaum RR; Schreiber H
Cancer Immunol Res; 2017 Feb; 5(2):127-136. PubMed ID: 28077434
[TBL] [Abstract][Full Text] [Related]
16. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
17. Light chain myeloma plasma cells induce a strong cell-mediated immune response mainly directed against the monoclonal light chain determinants in a murine experimental model.
Galea HR; Denizot Y; Cogné M
Cancer Immunol Immunother; 2002 Jun; 51(4):229-34. PubMed ID: 12012110
[TBL] [Abstract][Full Text] [Related]
18. Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer.
Knocke S; Fleischmann-Mundt B; Saborowski M; Manns MP; Kühnel F; Wirth TC; Woller N
Cell Rep; 2016 Nov; 17(9):2234-2246. PubMed ID: 27880900
[TBL] [Abstract][Full Text] [Related]
19. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models.
Corthay A; Lundin KU; Munthe LA; Frøyland M; Gedde-Dahl T; Dembic Z; Bogen B
Cancer Immunol Immunother; 2004 Sep; 53(9):759-69. PubMed ID: 15088126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
